ABSTRACT

Introduction

Prostate cancer (PCa) is one of the most common cancers worldwide and a leading cause of cancer-related mortality. Although the diagnosis and treatment of prostate cancer has improved substantially in recent years, new molecular biomarkers are needed to further prolong survival and improve the quality of life in these patients.

Areas covered

This review analyzes the current evidence for prognostic and predictive molecular biomarkers that can be applied across different clinical scenarios, ranging from localized disease to metastatic castration-resistant PCa, with a particular emphasis on the biomarkers likely to become available in routine clinical practice in the near future.

Expert opinion

There is a growing need for molecular testing to identify the most indolent types of prostate cancer to help optimize treatment strategies and spare treatment in these patients when possible. Current trends in the treatment of prostate cancer underscore the unmet clinical need for biomarkers to improve decision-making in a challenging clinical setting.

中文翻译：

---

前列腺癌临床医生的基因检测。

摘要

介绍

前列腺癌 (PCa) 是全球最常见的癌症之一，也是癌症相关死亡的主要原因。尽管近年来前列腺癌的诊断和治疗有了显着改善，但仍需要新的分子生物标志物来进一步延长这些患者的生存期并提高生活质量。

覆盖区域

本综述分析了可应用于不同临床情况的预后和预测分子生物标志物的当前证据，从局部疾病到转移性去势抵抗性 PCa，特别强调可能在近期常规临床实践中可用的生物标志物。未来。

专家意见

越来越需要分子检测来识别最惰性的前列腺癌类型，以帮助优化治疗策略并尽可能减少对这些患者的治疗。前列腺癌治疗的当前趋势强调了对生物标志物的未满足的临床需求，以在具有挑战性的临床环境中改善决策。